AMTURNIDE
LOE ApproachingNDAORALTABLET
Approved
Dec 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMTURNIDE is an oral small-molecule tablet approved by Novartis in December 2010. The generic name and mechanism of action are not publicly detailed in available records. It is formulated as a combination therapy targeting hypertension management.
LOE Approaching
Product is in late-stage commercial lifecycle with moderate competitive pressure (30/100), signaling potential team restructuring and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AMTURNIDE in its LOE-approaching phase offers limited growth upside but valuable experience in defensive market strategy, generic containment, and managed care negotiations. This role is best suited for professionals seeking to develop expertise in late-stage product stewardship rather than launch momentum.
Brand ManagerMedical Science Liaison
Worked on AMTURNIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.